89bio Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Rohan Palekar
Chief executive officer
US$5.6m
Total compensation
CEO salary percentage | 10.9% |
CEO tenure | 6yrs |
CEO ownership | 0.2% |
Management average tenure | 4.3yrs |
Board average tenure | 4.1yrs |
Recent management updates
Recent updates
89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy
May 2389bio Still Has A Chance As NASH Race Heats Up
Oct 0689bio completes enrollment in phase 2 trial for NASH treatment
Aug 1889Bio rallies on Deep Track Capital disclosing 10% stake
Jul 0789bio: Undervalued Contender In Race For First NASH Drug Approval
Jul 20We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely
May 0789bio: NASH Drug Developer With Differentiated Profile
Jan 29We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely
Jan 2289bio expects to initiate Phase 2b NASH trial in 1H21
Jan 05CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -US$165m |
Dec 31 2023 | US$6m | US$611k | -US$142m |
Sep 30 2023 | n/a | n/a | -US$127m |
Jun 30 2023 | n/a | n/a | -US$119m |
Mar 31 2023 | n/a | n/a | -US$105m |
Dec 31 2022 | US$3m | US$588k | -US$102m |
Sep 30 2022 | n/a | n/a | -US$104m |
Jun 30 2022 | n/a | n/a | -US$105m |
Mar 31 2022 | n/a | n/a | -US$101m |
Dec 31 2021 | US$5m | US$565k | -US$90m |
Sep 30 2021 | n/a | n/a | -US$76m |
Jun 30 2021 | n/a | n/a | -US$63m |
Mar 31 2021 | n/a | n/a | -US$54m |
Dec 31 2020 | US$5m | US$530k | -US$49m |
Sep 30 2020 | n/a | n/a | -US$56m |
Jun 30 2020 | n/a | n/a | -US$60m |
Mar 31 2020 | n/a | n/a | -US$64m |
Dec 31 2019 | US$1m | US$431k | -US$57m |
Sep 30 2019 | n/a | n/a | -US$44m |
Jun 30 2019 | n/a | n/a | -US$30m |
Dec 31 2018 | US$708k | US$195k | -US$18m |
Compensation vs Market: Rohan's total compensation ($USD5.59M) is above average for companies of similar size in the US market ($USD3.37M).
Compensation vs Earnings: Rohan's compensation has increased whilst the company is unprofitable.
CEO
Rohan Palekar (58 yo)
6yrs
Tenure
US$5,587,661
Compensation
Mr. Rohan Palekar serves as the Chief Executive Officer and Director at 89bio, Inc. since July 16, 2018. He is an Independent Director at Neoleukin Therapeutics, Inc since March 02, 2022 and Neurogene Inc....
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 6yrs | US$5.59m | 0.25% $ 1.9m | |
Chief Technical Officer | 5.3yrs | US$2.51m | 0.13% $ 1.0m | |
Chief Medical Officer | 5.6yrs | US$2.54m | 0.070% $ 534.0k | |
Chief Financial Officer | 5yrs | no data | 0.034% $ 260.2k | |
Senior Vice President of Finance & Principal Accounting Officer | no data | no data | no data | |
VP of Investor Relations & Corporate Communications | less than a year | no data | no data | |
Vice President of People & Culture | 3.5yrs | no data | no data | |
Senior Vice President of Commercial Strategy | no data | no data | no data | |
Senior Vice President of R&D Operations | 2.5yrs | no data | no data | |
VP & Head of Quality | 1.5yrs | no data | no data |
4.3yrs
Average Tenure
58yo
Average Age
Experienced Management: ETNB's management team is considered experienced (4.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 6yrs | US$5.59m | 0.25% $ 1.9m | |
Independent Director | 2.7yrs | US$360.17k | 0% $ 0 | |
Independent Director | 3.9yrs | US$363.33k | 0% $ 0 | |
Independent Director | 6.3yrs | US$358.33k | 0.25% $ 1.9m | |
Independent Director | less than a year | no data | no data | |
Independent Chairman of the Board | 4.3yrs | US$385.83k | 0% $ 0 | |
Independent Director | 2.4yrs | US$354.60k | 0% $ 0 | |
Independent Director | 6.3yrs | US$352.33k | 0% $ 0 |
4.1yrs
Average Tenure
60.5yo
Average Age
Experienced Board: ETNB's board of directors are considered experienced (4.1 years average tenure).